Syngene’s Q1 FY27: a sharp slowdown, and a clear reset under new leadership

Syngene entered FY27 with a difficult first quarter and a leadership transition. Siddharth Mittal assumed charge as Managing Director and CEO on July 1, 2026, while the Board and management framed FY27 as a year of course correction and strategic renewal.

Financially, the quarter was weak. Revenue from operations fell to INR 736 crore, down 16% year on year. Operating profitability compressed sharply, with operating EBITDA margin (excluding other income) at 12.3% versus 23.6% in Q1 FY26. Profit after tax before exceptional items was just INR 1 crore, and after exceptional items Syngene reported a loss of INR 9 crore.

Management attributed the quarter’s performance to two specific drivers: the lack of offtake from a major large molecule CDMO client and a sharp foreign exchange loss. The investor presentation and concall repeatedly pointed to the absence of Zoetis offtake in the quarter, alongside a net forex loss of INR 50 crore.

What drove the quarter: customer concentration and forex loss

The company’s commentary was unusually direct on concentration risk. Management acknowledged that over the past few years, the biologics manufacturing business became disproportionately dependent on a single large customer. The impact of that dependence became visible in Q1 FY27 when offtake did not materialize.

At the same time, Syngene also pointed to attrition in its commoditized research service offerings. The Chairperson noted that pricing pressure is inevitable in commoditized services and that Syngene did not want to compete in a “race to the bottom.” This choice helped protect long-term positioning, but it also meant near-term revenue pressure as low-margin work was deprioritized.

Financial summary (Q1 FY27)

Note: Operating EBITDA margin excludes other income. PAT before exceptional items excludes INR 10 crore net of tax related to termination benefits.

Business mix: Research Services still dominates, CDMO remains the swing factor

In the earnings call, management stated that Research Services accounted for 78% of sales in Q1 FY27, while CDMO contributed 22%. On an implied basis, that places Research Services revenue at about INR 574.1 crore and CDMO revenue at about INR 161.9 crore for the quarter.

This mix matters because the performance shock came largely from the manufacturing side. The absence of large molecule offtake, especially from a major client, can quickly reduce utilization and dilute margins in capital-intensive facilities.

Strategy reset: commercial engine, CDMO focus, and moving up the value chain

Management described FY27 as a rebuilding year rather than one for maximizing growth. The strategic direction has five repeated themes.

First, Syngene wants a stronger commercial engine. The Chairperson said winning business and deepening customer relationships will be central to the growth agenda. The company is strengthening its commercial organization under Abhijit Zutshi, with sharper market segmentation and more focused business development.

Second, CDMO is being reaffirmed as the primary long-term growth engine. Management argued that the industry continues to offer opportunity for partners with scientific depth, development expertise, and world-class manufacturing capabilities. In effect, Syngene is signaling a pivot away from more commoditized research work and toward higher-value, integrated programs.

Third, Syngene is pushing deeper into differentiated discovery capabilities, with a strong emphasis on artificial intelligence. In Q1 FY27, the company highlighted progress in Syn.AI. It said it built gigascale virtual screening capabilities to screen and prioritize larger libraries of molecules and advanced AI-driven de novo design to speed up novel molecule design and optimization. Management linked these investments to productivity and speed to science.

Fourth, the company is expanding capabilities in translational science and clinical research. Syngene signed an MoU with BRIC-THSTI to establish a joint operational partnership for early and late-phase clinical development, translational research and bioanalytical sciences. Management said the collaboration can enable first-in-human and Phase I programs along with biomarker and patient-based clinical research.

Fifth, operational excellence remains a key pillar. Management emphasized cost optimization actions already underway, and the company highlighted Lean Six Sigma deployment, digitized quality systems, and extensive audit history.

Facilities and utilization: Mangalore, Stelis, and the Bayview question

Syngene’s near-term growth outlook hinges on filling newly created capacity and improving utilization.

In small molecule CDMO, management pointed to Mangalore, stating the site had low utilization in prior years. It said there have been “very good discussions and few lock-ins” for both commercial and clinical molecules and guided for a utilization ramp-up during FY27, continuing into FY28.

On the Stelis facility acquisition, management said customers have already signed up and batches have been taken, with ramp-up expected during FY27 and continuing into FY28. However, it cautioned that most molecules there are still in clinical or development stages, with no large-volume commercial molecule currently expected from that unit.

Bayview, the US biologics site in Baltimore, is a strategic asset but not yet a revenue engine. Management stated the facility is planned to be operationalized later in FY27. Customers are visiting and evaluating the site, but customer commitments are expected after operationalization. Management also clarified that the facility will not be capitalized during FY27 under its accounting policy, implying minimal expenses in the P&L this year.

Guidance: weak H1, better H2, and a margin recovery target

Syngene provided explicit guidance for FY27.

For the full year, management expects a single-digit revenue decline in rupee terms. It also guided to EBITDA margins in the mid-20s, despite the weak Q1. Management linked this expectation to improving momentum in the second half, seasonality where Q4 is typically the strongest quarter, and continued cost saving initiatives.

On the Zoetis relationship, management said it is not completely zero but will be a very small percentage, noting Zoetis has inventory for the next couple of years. It also said it does not expect the molecule to be zero in FY28 and expects Zoetis to provide a forecast for FY28 by the end of FY27.

Takeaways: a difficult quarter, but clearer accountability

Q1 FY27 highlighted the operational downside of customer concentration in biologics CDMO and the earnings sensitivity to forex movements. But it also brought a clearer management narrative on what went wrong and what is being changed.

Syngene is positioning FY27 as a transition year where commercial execution is rebuilt, CDMO becomes the center of gravity, and differentiated discovery capabilities are strengthened using AI and translational science. The near-term test will be whether H2 delivers the revenue pickup and margin normalization implied by the mid-20s guidance, while utilization ramps at Mangalore and newer manufacturing assets progress from capability to committed customer demand.